
News|Articles|July 30, 2007
BREAKING NEWS: FDA Advisers Recommend Diabetes Drug Stay on Market
Author(s)Peggy Peck
Gaithersburg, Md. -- By a vote of 20 to three a group of FDA advisers found evidence that rosiglitazone (Avandia), the popular oral anti-diabetes drug, increases the risk of myocardial infarction. But the same advisers said the drug should stay on the market.
Advertisement
GAITHERSBURG, Md. July 30 -- By a vote of 20 to three a group of FDA advisers found evidence that rosiglitazone (Avandia), the popular oral anti-diabetes drug, increases the risk of myocardial infarction. But the same advisers said the drug should stay on the market.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement









